Riverhead Capital

Riverhead Capital, established in January 2015, operates as the private equity division of Sunshine Insurance Group in Beijing, China. As one of the initial insurance private fund pilot units sanctioned by the China Insurance Regulatory Commission, it manages assets totaling 17 billion yuan. The firm focuses on investments across various sectors, including healthcare, emerging industries, industrial mergers and acquisitions, and real estate. Its approach encompasses a range of strategies such as entrepreneurial support, strategic and financial investments, mergers and acquisitions, corporate restructuring, and cross-border investments. Riverhead Capital aims to enhance corporate value and promote the sustainable development of businesses, having already invested in multiple companies within medical, pharmaceutical, internet, and innovative financial services sectors.

Shenghao Shi

Managing Partner

31 past transactions

Hisky Medical

Series D in 2025
Hisky Medical is a company based in Beijing, China, established in 2010, that specializes in the development, manufacturing, and marketing of medical equipment aimed at non-invasive liver diagnosis. The firm focuses on innovative technologies for disease diagnosis and has developed a product called FibroTouch, which is designed to facilitate the assessment of liver conditions without the need for invasive procedures. Through its advancements in medical technology, Hisky Medical aims to improve diagnostic accuracy and patient comfort in the evaluation of liver health.

Nanos Medical

Venture Round in 2025
Nanos Medical specializes in the research, development, manufacturing, and sales of disposable medical devices, primarily targeting the cardiovascular and ear, nose, and throat (ENT) fields. The company offers a range of innovative products, including sinus balloon catheters, eustachian tube balloons, disposable nasopharyngeal airways, nasolacrimal balloons, and drug-eluting stents for sinus applications. Through its advanced medical devices, Nanos Medical aims to enhance treatment options for hospitals and patients, contributing to improved healthcare outcomes.

Unisic Technology

Series B in 2024
Unisic Technology specializes in designing and manufacturing silicon carbide core power components and semiconductor modules. The company develops a range of products utilizing third-generation silicon carbide materials, including semiconductor power modules and driver circuits. Unisic applies its silicon carbide technology across various critical sectors such as aviation, new energy power generation, high-end medical care, oil exploration, lighting, new energy vehicles, and data centers. By offering customized application solutions, Unisic Technology addresses the unique needs of its clients in these important fields, enhancing the performance and efficiency of power systems.

AaltoSemi

Private Equity Round in 2024
AaltoSemi is a developer and manufacturer of integrated circuit (IC) substrate products essential for semiconductor packaging. The company offers comprehensive services encompassing research and development, design, production, and testing of substrates, including BT and ABF types. AaltoSemi's product lineup features Coreless, ETS, FCCSP, FCBGA (BT), and FCBGA (ABF) substrates, which are crucial for facilitating communication between chips and circuit boards. As the demand for advanced semiconductor solutions grows, particularly in the automotive electronics sector, AaltoSemi focuses on achieving high precision, quality, reliability, and scalability in its substrate production. The company's offerings support the development of a variety of high-performance devices, including CPUs, GPUs, FPGAs, network ASICs, and 5G mobile phones, thereby addressing the evolving challenges posed by Moore's Law and the expanding market needs.

Ningkang Ruizhu

Series A in 2023
Rezubio Pharmaceuticals is a biotech company that focuses on technologies to deliver drugs to diseased tissues or organs, maximizing the desired efficacies while minimizing the adverse effects. They concentrate on oncology, metabolic disease, and immunology as specific disease areas.

Medical Source

Series B in 2023
Yiyuan Medical Technology is a high-tech enterprise specializing in the research and development, production, sales, technical services and technical consultation of medical CT tubes.

Bio-Engine

Series C in 2023
Bio-Engine is a company based in Shanghai, China, focused on the research and development of veterinary biological products. Founded in 2014, Bio-Engine specializes in creating and producing antibodies, recombinant proteins, and vaccines for both humans and livestock using serum-free suspension culture technology for animal cells. The company's expertise extends to providing clinical trial services for pharmaceutical manufacturers and scientific research units.

D2M Biotherapeutics

Series A in 2023
D2M Biotherapeutics focuses on the development of novel immunotherapeutics. The company is a tumor immunological drug developer that aims to expand the potential of immunotherapy.

Sijie Microelectronics

Series C in 2023
Sijie Microelectronics produces sensors and internet-of-things technology. Their product applications include car radar, security systems, smart bathrooms, smart transportation, level measurement, parking detection, smart IoT, smart appliances, and more.

Huzhou Shenke

Series B in 2023
Huzhou Shenke is a biotechnology company specializing in the research and development of key technologies and products for biological products. It offers detection technical services and standardized detection kits, with a focus on nucleic acid analysis. The company's product portfolio includes fluorescent quantitative PCR instruments, digital PCR instruments, protein purification systems, and other professional research equipment, aiming to provide safe and reliable medical products.

Cell Probio

Series B in 2022
Cell Probio is a manufacturer of cell culture consumables, positioned in the R&D, production and sales of high-end biological consumables.

WuXi Bo Rui Biotechnology

Series A in 2022
WuXi Bo Rui Biotechnology develops a radioactive molecular imaging and nuclear drug transformation platform for the precise diagnosis and treatment of tumors. WuXi Bo Rui Biotechnology focuses on the transformation and development of new radionuclide drugs, covering multiple fields of small molecules, peptides, and antibodies, for the diagnosis and treatment of tumors, using their professional platform for targeted precursor design, screening, and radionuclide labeling. While increasing the efficiency of research and development, it also fully utilizes the benefits of accurate nuclear medicine diagnosis and treatment

Yingsheng Biology

Series B in 2020
Yingsheng Biotechnology Co., Ltd., established in 2009, specializes in the development of in vitro diagnostic reagents and medical equipment focused on maternal and child health, neonatal genetic diseases, metabolic disorders, and birth defects. The company offers a diverse product line that includes 45 innovative screening reagents for genetic metabolic diseases, deaf genetic testing kits, vitamins determination reagents, and an HLA-B27 detection kit. Yingsheng also provides advanced diagnostic technologies such as a mass spectrometer automatic intelligent processing platform and ultra-high performance liquid chromatography tandem mass spectrometry detection systems. Through its innovative products, Yingsheng aims to facilitate early detection of genetic conditions, promoting timely intervention and better health outcomes for patients.

Sirnaomics

Series D in 2020
Sirnaomics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing targeted therapeutics for significant human diseases using RNA interference (RNAi) technology. Founded in 2007 and headquartered in Gaithersburg, Maryland, with additional offices in Cambridge, Massachusetts, and facilities in Suzhou and Guangzhou, China, Sirnaomics is dedicated to addressing critical medical needs in oncology, anti-fibrotic therapeutics, and viral infections. The company's product portfolio includes several small interfering RNA (siRNA) therapeutics such as STP705 for scar reduction, STP909 for colon cancer, and STP900 for HPV and cervical cancer, among others. Sirnaomics employs proprietary Polypeptide Nano-Particle (PNP) technology to enhance drug delivery, allowing effective targeting of the tumor microenvironment and various cell types, particularly in the liver. Through its innovative approach, Sirnaomics aims to create impactful treatments for diseases with large market opportunities.

Lepu Bio

Series B in 2020
Lepu Biotechnology Co., Ltd. is a Chinese biotech company specializing in tumor immunotherapy. Founded in 2018, it has developed an industrial platform dedicated to target discovery, drug preparation, development, and manufacturing. The company focuses on creating drug candidates that include programmed death-1 (PD-1) and programmed death-ligand 1 (PD-L1) antibodies, an oncolytic virus, and various antibody-drug conjugates (ADCs). Lepu Bio's core products are currently in clinical stages I to III, demonstrating its commitment to advancing cancer treatment through innovative biopharmaceutical solutions.

Ruipeng Pet Healthcare

Venture Round in 2020
Ruipeng Pet Hospital, located in Shenzhen, specializes in a comprehensive range of pet care services. The hospital provides medical and beauty care for pets, including healthcare, foster care, bathing, SPA treatments, grooming, food, and entertainment. By offering both digital and clinical services, Ruipeng aims to ensure that pet owners can access high-quality care for their animals efficiently. The organization also includes online shopping options to further support pet owners in meeting their pets' needs.

AW Education International

Series B in 2020
AW Education International is an overseas education consulting firm specializing in study abroad services for high school, university, and Master's students in China. The company provides a comprehensive one-stop service platform that assists families in navigating the complexities of international education. Its offerings include preparation for English proficiency and university entrance exams, as well as access to internship and volunteer opportunities that enhance students' resumes. By focusing on destinations in North America, Europe, Australia, and Asia, AW Education International aims to facilitate a seamless transition for students pursuing educational opportunities abroad.

ESWIN Computing

Series B in 2020
ESWIN Computing is a company specializing in the research and development of RISC-V computing architecture. It focuses on the design, testing, and material aspects of integrated circuits for Internet of Things (IoT) applications, particularly in display devices and wearable technology. ESWIN provides comprehensive solutions for various sectors, including artificial intelligence, the Internet of Vehicles, and human-computer interaction, aiming to enhance user experiences in these rapidly evolving fields.

Sunny Dental

Series A in 2020
Sunny Dental, founded in 2007 and based in Beijing, China, specializes in a comprehensive range of orthodontic services. The company provides diagnosis and treatment for dental implants, children’s dentistry, dental restorations, periodontal disease, dental pulp issues, and oral and maxillofacial surgery. Sunny Dental is dedicated to offering professional care and advanced solutions in various aspects of dental health, ensuring a focus on both preventative and restorative treatments.

Chao Ju Ophthalmology

Series C in 2019
Chao Ju Ophthalmology Hospital is a prominent healthcare provider specializing in ophthalmic treatments, particularly laser and refractive eye surgeries. Established in 1988 and headquartered in China, the hospital boasts over 30 years of operational experience in the field of ophthalmology. With a workforce exceeding 2,000 professionals, including professors, researchers, and senior medical practitioners, Chao Ju Ophthalmology is recognized for its strong technical expertise. The organization operates more than 100 medical clinics staffed by clinical professors, ensuring high-quality care and advanced treatment options for patients.

Enflame Technology

Series A in 2019
Enflame Technology specializes in developing neural network solutions tailored for artificial intelligence applications. The company's primary offerings include high-end deep learning chips designed specifically for cloud data centers and AI training platforms. These chips feature a proprietary architecture that emphasizes high computational power and energy efficiency, while also being programmable and cost-effective. Enflame Technology's products are optimized for mainstream machine learning frameworks, making them suitable for a wide range of AI training and optimization tasks.

Rundo Medical

Series C in 2019
Rundo Medical is a contract research organization (CRO) that focuses on providing comprehensive clinical research outsourcing services to pharmaceutical and biotechnology companies. It specializes in a range of high-quality solutions, including clinical operations, medical data management, biostatistics, and medical project management. As a prominent player in the CRO industry, Rundo Medical is a key initiator and promoter of the China CRO Alliance. The company has distinguished itself by being the first in its sector to achieve ISO 9001:2008 quality management system certification, combined with CRO industry standard certification. Through its professional services, Rundo Medical supports various clients in advancing their medical research and operational objectives.

Lionbridge Financing Leasing

Corporate Round in 2018
Lionbridge is a commercial vehicle smart finance and service platform that creatively combines financial capital and industrial operation. It specializes in services for industries such as logistics transportation, auto finance, health care, new energy & new equipment, etc. The company is committed to the concept of connecting symbiosis and uses technology tools and financial instruments to empower partners to develop new operating models and gain greater value. Lionbridge was founded in 2012 and is based in Beijing, China. In September 2014, the company was acquired by [Bain Capital](/organization/bain-capital-2), a US-based private equity firm.

Meilianzhonghe Veterinary Hospital

Series A in 2017
Meilianzhonghe Veterinary Hospital offers pet diagnosis and treatment services. It offers services to the pet medical industry. The company's services include pet grooming, pet care, and pet training.

Ruipeng Pet Healthcare

Corporate Round in 2017
Ruipeng Pet Hospital, located in Shenzhen, specializes in a comprehensive range of pet care services. The hospital provides medical and beauty care for pets, including healthcare, foster care, bathing, SPA treatments, grooming, food, and entertainment. By offering both digital and clinical services, Ruipeng aims to ensure that pet owners can access high-quality care for their animals efficiently. The organization also includes online shopping options to further support pet owners in meeting their pets' needs.

QingCloud

Series D in 2017
QingCloud is a technology enterprise based in China that offers a cloud computing platform focused on Infrastructure as a Service (IaaS). The company provides a range of flexible cloud services, including private networking, real-time computing, open APIs, comprehensive monitoring, and robust security policies. Founded by former employees of Tencent, Baidu, and IBM, QingCloud aims to create an optimized IaaS platform that meets significant technological needs. The company's CEO has articulated a vision for QingCloud to emerge as a globally recognized cloud provider. With plans to expand its operations into the Asia Pacific region, QingCloud is committed to delivering innovative, reliable, and flexible solutions that support digital transformation for enterprises.

Miao

Series A in 2016
MORE Health’s is a heath startup that aims to offer access to the best physicians in the world when they are needed the most; when patients are faced with a critical, potentially life-changing illness, such as cancer or heart disease. More health started as an incubation project under Chinese conglomerate SanPower Group.

Yangguang Huxin

Angel Round in 2016
Yangguang Huxin provides financial service and consumer installment services.

Yingyuqu Peiyin

Seed Round in 2016
Hangzhou Feizhu Technology is an English learning platform that conducts research and develops oral English education products. They provide dubbing practice, enabling English learners to improve their spoken English. They change the future of the online education industry by integrating social resources with the mobile Internet and providing English learners with an interesting, trendy, and scientific learning platform.

You Liang Sheng Huo

Angel Round in 2015
You Liang Sheng Huo is a food delivery company that specializes in providing catering services to enterprises. The company focuses on sourcing and purchasing ingredients centrally, ensuring strict controls over their origin and quality. This attention to quality allows You Liang Sheng Huo to deliver high-quality meals that maintain consistent taste. As a result, the company has established a strong reputation among its customers, leading to a high volume of repeat orders.

Mass Medical International

Angel Round in 2015
Mass Medical International operates a platform offering Chinese clients access to global healthcare services. Their offerings include international expert consultations, overseas medical treatments, high-end physical examinations, precision medicine, along with training programs for medical professionals and hospital management consulting services. The company aims to facilitate easy access to worldwide diagnostic and treatment services for its customers.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.